acut
respiratori
tract
infect
major
caus
morbid
mortal
worldwid
exert
consider
econom
burden
healthcar
system
acut
respiratori
tract
infect
upper
lower
respiratori
tract
caus
wide
varieti
viral
bacteri
pathogen
requir
comprehens
laboratori
investig
convent
serolog
immunofluorescencebas
diagnost
method
acut
respiratori
tract
infect
lack
sensit
compar
polymeras
chain
reaction
pcr
base
approach
develop
new
diagnost
methodolog
requir
provid
accur
sensit
rapid
diagnos
present
studi
pcrbase
low
densiti
oligonucleotid
microarray
develop
detect
viral
two
atyp
bacteri
pathogen
perform
dna
microarraybas
analysi
exhibit
compar
sensit
specif
multiplex
realtim
revers
transcript
polymeras
chain
reaction
rtpcr
confirm
potenti
diagnost
util
method
contrast
routin
multiplex
pcr
microarray
incorpor
intrins
redund
multipl
nonident
probe
per
target
array
allow
direct
intraassay
confirm
posit
studi
demonstr
microarray
technolog
provid
viabl
altern
convent
serologicalbas
approach
multiplex
pcr
pathogen
identif
acut
respiratori
tract
infect
acut
respiratori
tract
infect
common
reason
gener
practition
visit
acut
admiss
hospit
winter
season
irrespect
age
gender
elliot
et
al
lower
respiratori
tract
infect
account
million
death
worldwid
death
year
viral
bacteri
coinfect
frequent
observ
use
pcrbase
investig
mani
case
detect
current
serologicalbas
direct
antigen
detect
method
therefor
develop
new
diagnost
method
requir
enabl
detect
broad
rang
pathogen
inde
accur
sensit
rapid
differenti
diagnosi
influenc
patient
manag
reduc
potenti
inappropri
antibiot
use
aid
infect
control
measur
institut
set
current
serologicalbas
method
diagnosi
acut
respiratori
tract
infect
limit
assay
specif
sensit
often
result
underdiagnosi
eg
antigen
detect
adenovirida
arnold
et
al
howev
viral
antigen
detect
test
use
increasingli
low
demand
equip
cost
effect
grandien
addit
viru
isol
slow
expens
labour
intens
often
requir
day
incub
detect
confirm
absenc
cytopath
effect
addit
decreas
resourc
fewer
clinic
laboratori
appropri
facil
expertis
undertak
culturebas
investig
koenig
et
al
culturebas
method
also
use
bacteri
detect
also
hamper
slow
turnaround
time
report
result
insuffici
sensit
peter
et
al
serolog
profil
also
use
often
howev
requir
two
week
antibodi
develop
sequenti
sampl
often
collect
usual
requir
confirm
diagnosi
nilsson
et
al
wong
et
al
advanc
molecular
diagnost
method
enabl
rapid
diagnosi
infecti
diseas
murata
molecular
techniqu
offer
sever
advantag
convent
serologybas
method
includ
speed
eas
standardis
autom
high
assay
sensit
specif
dong
et
al
date
dna
microarray
technolog
use
predominantli
gene
express
profil
studi
basic
research
applic
hegd
et
al
clinic
present
acut
respiratori
tract
infect
divers
nonspecif
therefor
effici
laboratori
assay
detect
panel
common
respiratori
pathogen
would
advantag
addit
largescal
screen
may
identifi
coinfect
would
detect
previous
microarraybas
analysi
costeffect
approach
yield
reproduc
result
allow
replic
analys
singl
assay
run
achiev
spot
solid
phase
array
multipl
copi
probe
altern
probe
within
target
amplicon
andor
mismatch
probe
allow
intraassay
confirm
result
readili
possibl
multiplex
rtpcrbase
approach
novel
nonfluoresc
lowcost
low
densiti
oligonucleotid
microarray
format
develop
facilit
use
dna
microarray
clinic
diagnost
purpos
arraytub
tm
platform
offer
fulli
autom
system
clinic
diagnosi
sever
studi
use
platform
varieti
applic
borel
et
al
sachs
et
al
sachs
et
al
system
repres
costeffect
platform
involv
mm
mm
glass
biochip
integr
bottom
standard
ml
plastic
microtub
chip
may
contain
number
differ
probe
type
depend
specif
applic
allow
step
hybridis
reaction
conduct
within
vessel
obviat
requir
separ
hybridis
chamber
addit
laboratori
equip
hybridis
target
visualis
enzymecatalys
precipit
microtub
read
use
simpl
low
cost
transmiss
scanner
previou
studi
reveal
specif
hybridis
virusspecif
oligonucleotid
probe
obtain
singl
pcr
amplifi
target
copi
develop
oligonucleotid
microarraybas
system
detect
differenti
subtyp
viral
bacteri
respiratori
pathogen
simultan
compris
virus
two
atyp
bacteria
describ
pcrderiv
amplicon
extern
qualiti
assess
panel
known
posit
sampl
use
target
establish
probe
sensit
valid
panel
assembl
compris
throat
swab
specimen
collect
adult
present
symptom
respiratori
diseas
tertiari
care
hospit
winter
season
evalu
potenti
role
microarray
assay
compar
multiplex
rtpcr
oligonucleotid
probe
genom
target
region
list
tabl
oligonucleotid
probe
evalu
use
http
frodowimitedu
probe
array
nucleotid
base
length
modif
exist
taqman
assay
import
paramet
modif
exist
publish
taqman
probe
would
similar
valu
hybridis
would
uniform
denatur
amplicon
array
probe
valu
close
averag
probe
valu
calcul
use
use
santalucia
method
calcul
santalucia
oligonucleotid
probe
metabion
martinsri
germani
bp
length
spot
fourfold
redund
glass
array
use
proprietari
technolog
arraytub
clondiag
technolog
jena
germani
biotinyl
endpoint
pcr
primer
sequenc
multiplex
setup
shown
tabl
onestep
rtpcr
kit
qiagen
crawley
uk
use
accord
manufactur
instruct
modifi
addit
mm
dttp
mm
datp
dgtp
dctp
mm
per
reaction
anneci
ltd
lancast
uk
target
label
pcr
condit
cycl
c
min
cycl
c
min
cycl
c
c
min
c
min
final
extens
cycl
c
min
thermocycl
mj
research
waltham
usa
microarray
wash
nucleasefre
water
promega
madison
wi
usa
hybridis
buffer
mm
napoi
ph
camida
ltd
tipperari
ireland
sd
mm
edta
ph
ssc
sigma
dublin
ireland
min
c
rpm
thermomix
comfort
eppendorf
ag
hamburg
germani
l
volum
target
solut
final
volum
l
hybridis
buffer
heat
c
min
chill
ice
biotinyl
target
reaction
hybridis
microarray
c
h
rpm
dna
array
wash
solut
decreas
stringenc
ssc
triton
x
ssc
ssc
sigma
dublin
ireland
min
c
rpm
block
perform
use
bsa
triton
x
sigma
dublin
ireland
min
c
rpm
dilut
streptavidinhorseradish
peroxidis
sahrp
conjug
pierc
dublin
ireland
ad
min
c
rpm
wash
repeat
solut
decreas
stringenc
ssc
triton
x
ssc
ssc
sigma
dublin
ireland
min
c
rpm
remov
unbound
sahrp
conjug
visualis
hybridis
target
achiev
incub
l
tetramethyl
bendzidin
tmb
kpl
ltd
md
usa
c
min
hybridis
signal
measur
c
min
use
dna
microarray
transmiss
scanner
clondiag
technolog
jena
germani
quantit
stain
valu
qsv
local
background
correct
obtain
probe
spot
via
iconoclust
softwar
version
clondiag
technolog
jena
germani
criteria
assign
hybridis
pattern
follow
backgroundcorrect
signal
intens
given
ni
ni
normalis
intens
mean
spot
intens
bg
local
background
intens
spot
intens
measur
light
transmiss
valu
rang
complet
transmiss
background
weak
spot
complet
absorpt
dark
spot
normalis
intens
rang
corless
et
al
kuyper
et
al
e
dare
et
al
f
gunson
et
al
g
lu
et
al
h
gullsbi
et
al
qsv
report
median
four
replic
signal
probe
realtim
pcr
primer
sequenc
multiplex
setup
shown
tabl
carri
use
invitrogen
superscript
iii
onestep
qpcr
system
accord
manufactur
instruct
invitrogen
paisley
uk
intern
control
extract
effici
sampl
addit
absenc
pcr
inhibitor
specimen
amplifi
human
gene
kra
throat
swab
biotinyl
pcr
product
purifi
use
high
pure
pcr
product
purif
kit
accord
manufactur
instruct
elut
l
roch
appli
scienc
mannheim
germani
dna
concentr
determin
use
nanodrop
spectrophotomet
thermo
scientif
de
usa
dna
target
solut
normalis
ngl
seri
dilut
pgl
prepar
subject
dna
microarray
analysi
throat
swab
collect
adult
patient
respiratori
symptom
present
emerg
depart
tertiari
care
hospit
dublin
winter
season
swab
store
viral
transport
medium
c
process
dna
rna
extract
respiratori
specimen
use
qiaamp
viru
biorobot
mdx
kit
biorobot
mdx
workstat
accord
manufactur
instruct
qiagen
crawley
uk
develop
valid
diagnost
pcrbase
low
densiti
oligonucleotid
microarray
detect
viral
bacteri
respiratori
pathogen
initi
studi
oligonucleotid
microarray
probe
specif
assess
use
known
posit
specimen
ie
either
extern
qualiti
assess
sampl
clinic
materi
confirm
rtpcr
andor
sequenc
analyt
sensit
evalu
serial
dilut
biotinyl
target
amplicon
hybridis
array
tabl
list
qsv
individu
pathogen
probe
mean
intern
stain
control
background
signal
assay
background
signal
equival
neg
assay
well
factor
signal
greater
background
level
exclud
coronaviru
qsv
remain
probe
exhibit
qsv
median
qsv
intern
stain
control
qsv
minimum
factor
probe
signal
greater
background
factor
coronaviru
maximum
rsv
subtyp
b
certain
pathogen
multipl
probe
differ
sequenc
show
greater
specif
singl
probe
sequenc
eg
probe
respect
analyt
sensit
microarray
evalu
use
serial
dilut
individu
target
known
concentr
major
probe
exhibit
reduc
sensit
pg
target
dnacdna
complet
loss
signal
pg
target
dna
probe
data
shown
signal
observ
pg
target
dna
probe
rsv
subtyp
still
yield
qsv
approxim
cohort
clinic
specimen
test
multiplex
rtpcr
dna
microarray
analysi
n
assess
perform
dna
microarray
clinic
investig
result
summaris
tabl
tabl
illustr
clinic
sensit
dna
microarraybas
assay
realtim
pcr
c
valu
list
posit
specimen
alongsid
dna
microarray
result
six
target
detect
dna
microarray
analysi
weakli
posit
via
rtpcr
analysi
c
valu
c
valu
clinic
sampl
test
qsv
background
next
attempt
determin
clinic
relev
find
rtpcr
microarray
analysi
specimen
posit
dna
microarray
analysi
c
valu
rtpcr
includ
analysi
n
tabl
among
posit
test
result
two
patient
concomit
bacteri
respiratori
tract
infect
pneumonia
antibiot
treatment
implement
remain
patient
patient
admit
hospit
two
patient
admit
diagnosi
pneumonia
infiltr
chest
xray
posit
pneumonia
antibiot
treatment
therefor
consid
appropri
major
patient
neither
elev
peripher
white
cell
count
signific
chest
xray
infiltr
seem
plausibl
posit
viral
test
result
would
avail
clinician
less
antibiot
would
prescrib
current
diagnost
methodolog
detect
respiratori
pathogen
cell
cultur
isol
antigenantibodi
detect
immunofluoresc
conventionalrtpcr
howev
methodolog
sensit
specif
turnaround
time
requir
impact
clinic
manag
variat
sampl
qualiti
may
impact
viabil
viru
cultur
also
number
avail
cell
immunofluoresc
investig
wherea
pcr
less
impact
poor
sampl
qualiti
therefor
molecular
techniqu
requir
accur
rapid
diagnosi
pcr
test
consid
sensit
data
shown
combin
pcr
dna
microarraybas
assay
capabl
detect
identifi
pathogen
throat
swab
specimen
singl
run
studi
also
show
dna
microarray
assay
respiratori
pathogen
sensit
requir
test
clinic
sampl
ii
high
specif
capac
achiev
identif
differenti
pathogen
singl
test
singl
work
day
importantli
redund
spot
probe
multipl
nonident
probe
per
target
array
allow
direct
intraassay
confirm
posit
abil
perform
replic
analys
singl
assay
run
provid
major
advantag
realtim
technolog
limit
number
avail
dye
current
detect
technolog
platform
addit
precipit
stain
utilis
microarray
approach
describ
herein
problem
respect
signal
stabil
quench
effect
crosstalk
detector
encount
rtpcr
importantli
microarray
significantli
greater
multiplex
capabl
rtpcr
present
maximum
five
target
analys
per
well
best
practic
would
employ
one
filter
intern
control
leav
four
filter
detect
pathogen
per
reaction
addit
increas
concern
regard
accuraci
multipl
format
compar
amplif
simplex
reaction
pcrbase
dna
microarray
assay
fail
detect
number
sampl
report
weak
posit
rtpcr
howev
posit
c
valu
dubiou
clinic
signific
technolog
allow
differenti
diagnos
advantag
microarray
provid
clinic
relev
inform
technolog
inevit
impact
manag
strategi
respiratori
infect
potenti
could
employ
limit
outbreak
institut
well
decreas
empir
antibiot
usag
pathogen
respons
shown
viral
abil
attach
larg
number
probe
solid
phase
compar
low
cost
per
pathogen
test
oligonucleotid
microarraybas
assay
compar
multiplex
rtpcr
suggest
may
potenti
altern
clinic
test
furthermor
increas
capac
test
broaden
approach
diagnosi
patient
manag
time
molecular
test
result
contribut
good
antimicrobi
stewardship
help
prevent
secondari
complic
associ
antibiot
treatment
intraven
line
infect
potenti
toxicallerg
side
effect
patient
influenza
b
posit
test
result
two
admit
gener
medic
ward
admiss
influenza
patient
open
ward
pose
signific
infect
control
hazard
could
potenti
result
influenza
outbreak
molecular
test
respiratori
specimen
could
help
initi
appropri
isol
infect
control
measur
protect
patient
date
highdens
spot
dna
microarray
almost
exclus
use
research
purpos
broad
spectrum
applic
dankbar
et
al
gruden
et
al
scaria
et
al
sidder
et
al
howev
technolog
also
employ
clinic
laboratori
diagnosi
viral
pathogen
clinic
specimen
potenti
becom
frontlin
screen
assay
supplant
quantit
pcr
manag
herpesviru
adenovir
infect
immunocompromis
patient
popul
muller
et
al
highdens
situ
synthesis
dna
microarray
offer
greater
analyt
sensit
accommod
greater
number
probe
advanc
approach
analysi
eg
resequenc
microarray
lin
et
al
genotyp
lode
et
al
low
densiti
dna
microarraybas
analysi
costeffect
assay
concept
futur
combin
microarray
hybridis
highthroughput
autom
dna
extract
amplif
signific
impact
highthroughout
analysi
regard
role
spot
dna
microarray
diagnost
shown
suitabl
low
densiti
platform
avail
develop
diagnost
assay
though
less
sensit
may
paradox
benefit
identif
clinic
signific
level
pathogen
cost
eas
autom
incorpor
liquid
handl
multiplex
capabl
make
platform
attract
altern
techniqu
standardis
purpos
requir
clinic
diagnost
specif
relev
current
commerci
assay
meet
test
algorithm
particular
clinic
laboratori
may
impact
approach
specimen
test
clinic
laboratori
hospit
set
inevit
aid
detect
monitor
therapeut
treatment
diseas
dna
microarraybas
analysi
may
thu
potenti
altern
clinic
test
provid
inform
pathogen
allow
better
assess
viral
aetiopathogen
agent
respons
respiratori
ill
case
viral
bacteri
coinfect
